Hydra Biosciences, a US-based developer of renal diseases and disorders backed by pharmaceutical firms MedImmune, Eli Lilly and Biogen Idec, has raised $10.5m in funding, according to a regulatory filing.
The funding came shortly before Hydra signed a deal with another pharmaceutical company, Boehringer Ingelheim, to develop its transient receptor potential inhibitor technology.
Hydra has now raised about $79.5m in funding since it was founded in 2001. Its most recent round prior to its latest funding was a $22m series D round raised in 2009 from corporate venturing units MedImmune Ventures, Biogen-Idec Ventures, and Lilly Ventures, Advanced Technology Ventures, Abingworth, Polaris and BioVenture Investors.